Macular Degeneration

Aggressive clinical trials boost wet AMD therapeutics

Published in Biotech Business Week, October 11th, 2004

Back-of-eye disease therapeutics are gaining attention from pharmaceutical and biotechnology companies as advances in therapeutic technology offer hope for nearly 20.5 million people in the United States that suffer from age-related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME).

Wet AMD, the most aggressive form of AMD and visual impairment, is particularly lucrative with therapeutic developments such as angiogenesis inhibitors, gene vaccines, and vascular endothelial growth factor (VEGF).

New analysis from Frost & Sullivan, Strategic Analysis of the Age-Related Macular Degeneration, Diabetic Retinopathy, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-10-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry